Zu-Chian Chiang at Fujian Normal University, China.
Dr. Zu-Chian Chiang is a materials scientist and biomedical researcher specializing in antibody–drug conjugates (ADCs), aptamer-based therapeutics, and functional biomaterials for cancer therapy and regenerative medicine. With a strong foundation in chemical engineering and molecular design, his research spans across Taiwan and China, advancing innovative strategies in translational medicine.
Publication Profile
Scopus
Educational Details
-
Ph.D. in Materials and Chemical Engineering
National United University, Taiwan | Sept 2008 – Jul 2014
-
M.S. in Chemistry
Tunghai University, Taiwan | Sept 2005 – Aug 2007
Professional Experience
Dr. Chiang has extensive postdoctoral research experience in interdisciplinary biomedical research.
-
Postdoctoral Fellow
Fujian Normal University, Biomedical Research Center of Southern China (2019–Present)
Focus: Development of ADCs and aptamers in cancer therapy under Prof. Qi Chen.
-
Postdoctoral Fellow
Academia Sinica, Institute of Biological Chemistry (2016–2019)
Participated in the Taiwan Protein Project (TPP) and the TSPA platform, supervised by Academician Hui-Kung Wang.
-
Postdoctoral Fellow
Clinical Trial Center, National Taiwan University Hospital (2015–2016)
Selected for the 3rd Biotech Elite Training Reserve Program (MOST). Mentored by Dr. Chih-Hao Chang.
Teaching Experience
-
Served as a Teaching Assistant (2005–2013) in a wide range of chemistry and chemical engineering subjects including Organic Chemistry, Physical Chemistry, Thermodynamics, and Instrumental Analysis at both Tunghai University and National United University.
Research Interest
-
Design and synthesis of functional peptides for cancer therapy and bone tissue regeneration
-
Development of biomicro- and macromolecular composites for regenerative medicine
-
Engineering antibody–drug conjugates (ADCs) for targeted cancer treatment
-
Construction of aptamers as molecular blockers, agonists, or antagonists in oncology applications
Author Metrics
-
Total Publications: 7 peer-reviewed journal articles
-
Total Citations: 93 (as of latest data)
-
h-index: 5
-
Research Interest Score: 49.5 (ResearchGate metric)
Top Noted Publication
Development of Novel CD47-Specific ADCs Possessing High Potency Against Non-Small Cell Lung Cancer in vitro and in vivo
Authors:
Z.C. Chiang (Zu-Chian Chiang), S. Fang (Shubin Fang), Y. Shen (Yangkun Shen), D. Cui, H. Weng, D. Wang, Y. Zhao, J. Lin (Jizhen Lin), Q. Chen (Qi Chen)
Journal:
Frontiers in Oncology
Year: 2022
Volume: 12
Article ID: 857927
DOI: 10.3389/fonc.2022.857927
Access: Article • Open Access
Article Type: Original Research
Author Roles:
-
First Author: Zu-Chian Chiang
-
Co-first Author: Shubin Fang (#)
-
Corresponding Authors: Jizhen Lin*, Qi Chen*
Summary:
This study presents the design and evaluation of novel CD47-targeting antibody–drug conjugates (ADCs) with high antitumor efficacy against non-small cell lung cancer (NSCLC), demonstrating promising therapeutic potential both in vitro and in vivo.
Conclusion
Dr. Zu-Chian Chiang is an emerging talent in the biotechnology research community, with a clear trajectory toward impactful innovation in cancer therapy and regenerative medicine. His demonstrated strengths in antibody–drug conjugates, biomaterials design, and molecular therapeutics showcase both technical expertise and translational vision.